TEMPLE CITY, Calif., Oct. 07, 2016 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ:FLGT) (“Fulgent Genetics” or the “company”) announced today that the underwriters of its previously announced initial public offering have exercised in full their option to purchase 630,000 additional shares of the company’s common stock at a public offering price of $9.00 per share, before underwriting discounts. All of the additional shares were offered by Fulgent Genetics.
Credit Suisse Securities (USA) LLC and Piper Jaffray & Co. acted as joint book-running managers for the offering. Raymond James & Associates, Inc. acted as lead manager and BTIG, LLC acted as co-manager.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on September 28, 2016. The offering was made solely by means of a prospectus. A copy of the final prospectus relating to this offering may be obtained from: Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, Eleven Madison Avenue, New York, NY 10010, by telephone at +1-800-221-1037, or by email at email@example.com; or from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Suite 800, Minneapolis, MN 55402, by telephone at +1-800-747-3924, or by email at firstname.lastname@example.org.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Last updated on: 10/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.